Private labeler will take a "significant restructuring charge" in FY 2001 fourth quarter to cover costs of reengineering initiative that began in July 2000 and was accelerated in the fiscal third quarter ending Dec. 31, Leiner announces Feb. 14. Initiative includes elimination of 500 positions and closure of three facilities; manufacturing operations will be relocated to the firm's OTC facility in Fort Mill, S.C. (1"The Tan Sheet" Nov. 20, 2000, p. 4). Net sales for fiscal Q3 were down 12.7% to $159.5 mil. from the year-ago period; for the nine months, net sales were flat at $454.6 mil
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
In line with new President Lee’s campaign pledges, South Korea's newly confirmed health minister is expected to tackle key issues including a prolonged doctors' conflict, essential drug supplies and R&D support for the industry.
The removal of CBER Director Prasad comes after a wave of right-wing backlash to his appointment over the past few days that was also critical of his decision to ask Sarepta to suspend all sales of the DMD gene therapy Elevidys. FDA reversed its decision the day before Parsad's departure.
Meanwhile, companies continue discussions with the Trump Administration over ways of increasing what European nations pay for drugs as an alternative to imposing a Most Favored Nation drug pricing policy in the US.
